Cathy Kelly
Senior editor
Washington DC, USA
42+ years of experience
Pink Sheet
By Cathy Kelly 07 Jan 2021
Razor-thin majorities in both chambers of Congress mean Democrats can’t enact a bold agenda, and the pandemic and attendant recession mean that the initial legislative focus won’t be on Rx issues.
Pink Sheet
By Cathy Kelly 18 Nov 2020
A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 17 Nov 2020
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 25 Sep 2020
Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.
Topic US Election 2020 Drug Pricing
Pink Sheet
By Cathy Kelly 21 Sep 2020
Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.
Pink Sheet
By Cathy Kelly 18 Dec 2019
Bill addresses ‘dead zone’ for pending applications for protein products transitioning to biologic status; generic and brand industries each win in different legislative provisions: inclusion of the CREATES Act, and a revised definition for ‘biologics’ that includes chemically synthesized polypeptides.
Topic Biosimilars Legislation
Pink Sheet
By Cathy Kelly 09 Aug 2019
Investigation may help define when rebate arrangements seeking to protect a brand against biosimilar competition are anticompetitive.
Topic Policy & Regulation
Scrip
By Cathy Kelly 22 Mar 2019
Public statements by Novartis and Avexis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
Topic Drug Review Approvals
Pink Sheet
By Cathy Kelly 01 Feb 2019
Proposed US rule would establish two new safe harbors against anti-kickback enforcement, one covering price reductions at the point of sale and the other protecting flat service fees paid by manufacturers to pharmacy benefit managers. But rebates to "PBMs to buy formulary position" in Medicare/Medicaid would lose protection.
Scrip
By Cathy Kelly 19 Nov 2018
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.
Pink Sheet
By Cathy Kelly 26 Sep 2018
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
Pink Sheet
By Cathy Kelly 21 Sep 2018
Even though measure was blocked in Congress, it may still advance through regulation.
Pink Sheet
By Cathy Kelly 22 Aug 2018
Regulations allow manufacturers to request that drug production and marketing costs and price contracting information provided to the state be kept confidential.
Topic Approvals
Pink Sheet
By Cathy Kelly 22 Aug 2018
Companies should introduce same drug under new NDC at lower list price to overcome difficulties of reducing list prices on existing brands, PBM says.
Topic Policy & Regulation
Pink Sheet
By Cathy Kelly 06 Jun 2018
HHS Office of Inspector General traces reimbursement, pricing, rebating and utilization patterns for established brands from 2011 to 2015.
Pink Sheet
23 Jun 2022
Pink Sheet
22 Jun 2022
Pink Sheet
15 Jun 2022
Pink Sheet
13 Jun 2022
Pink Sheet
01 Jun 2022
Pink Sheet
01 Jun 2022
Pink Sheet
11 May 2022
Pink Sheet
03 May 2022
Pink Sheet
29 Apr 2022
HBW Insight
25 Apr 2022
Pink Sheet
30 Mar 2022
Pink Sheet
29 Mar 2022
Pink Sheet
16 Mar 2022
Pink Sheet
22 Feb 2022
Pink Sheet
16 Feb 2022